New York, NY, Jan. 31, 2024 (GLOBE NEWSWIRE) -- The latest research report [115+] pages with 360-degree visibility, titled “Antiparasitic Drugs Market Share, Size, Trends, Industry Analysis Report, By Type (Antiprotozoals, Anthelmintics, Others); By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024- 2032" published by Polaris Market Research in its research repository.
The global antiparasitic drugs market size and share is currently valued at USD 23.86 billion in 2023. It is anticipated to generate an estimated revenue of USD 38.20 billion by 2032, according to the latest study by Polaris Market Research. Besides, the report notes that the market exhibits a robust 5.4% Compound Annual Growth Rate (CAGR) over the forecasted timeframe, 2024-2032.
Market Definition
- What is Antiparasitic Drugs? How Big is Antiparasitic Drugs Market Size?
These medicines operate by terminating parasites, prohibiting their evolution, or paralyzing them. A parasite is a scaled-down microorganism. It can reside within the body or on the skin or hair of humans and animals. Parasites obtain their supplements from these people or animals. The rapidly rising demand for antiparasitic drugs can be attributed to varied kinds of earmarking of particular parasites. Some of the drugs have detrimental side effects. The provider will suggest an appropriate drug and dose-dependent on the parasite that created the infection.
The antiparasitic drugs market growth can be attributed to the fact that the population density influenced the populace, notably pushing the demand. Elements such as population growth, demographic switch, and urbanization impact the vulnerability to parasitic infections, generating an escalated requirement for an impactful cure. The existence of these infections in multiple age groups and demographics highlights the wide market demand. As populations dilate, especially in areas inclined to parasitic ailments, pharmaceutical firms react to advancing patient demographics by progressing and providing earmarked antiparasitic drugs.
Request a Free Sample Copy of Antiparasitic Drugs Market Research Report @ https://www.polarismarketresearch.com/industry-analysis/antiparasitic-drugs-market/request-for-sample
Our Sample Report May Includes:
- 2032 Updated Report Introduction, Overview, and In-depth industry analysis.
- 115+ Pages Research Report (Inclusion of Updated Research).
- Provide Chapter-wise guidance on Requests.
- 2023 Updated Regional Analysis with Graphical Representation of Size, Share & Trends.
- Includes Updated List of tables & figures.
- Updated Report Includes Top Market Players with their Business Strategy, Sales Volume, and Revenue Analysis.
Market’s Key Companies
- AstraZeneca
- Bayer AG
- Cipla Limited
- Dr. Reddy's Laboratories
- F. Hoffmann-La Roche Ltd.
- GlaxoSmithKline
- Ipca Laboratories Ltd
- Lupin Pharmaceuticals
- Merck & Co.
- Novartis
- Pfizer
- Sanofi
- Sun Pharmaceutical Industries Ltd.
- Viatris
- Zydus Group
Purchase a Full Detail Report With Complete TOC @ https://www.polarismarketresearch.com/buy/3251/2
Key Highlights
- Elements such as population growth, demographic switch, and urbanization impact the vulnerability to parasitic infections generating an escalated requirement for impactful cure driving the market growth.
- The antiparasitic drugs market segmentation is primarily based on type, route of administration, distribution channel, and region.
- North America dominated the market in 2023
Market Developments
- Growth Drivers:
Eliminating parasitic infections: Worldwide health capabilities are influential in propelling the demand for antiparasitic drugs, particularly earmarking widespread illnesses such as malaria, leishmaniasis, and helminth infections. The antiparasitic drugs market size is expanding due to their unwavering endeavors are concentrated on regulating and eliminating parasitic infections, particularly in regions struggling with upraised disease existence causing growing market demand. The alliance among governments, NGOs, and pharmaceutical structures is important, pooling resources and prowess to enhance the obtainability of productive antiparasitic drugs. As this inventiveness acquires propulsion, there is a growing consciousness that stimulates premature diagnosis and cure. This mutual allegiance notably boosts the significance of antiparasitic drugs pushing market expansion, resulting in comprehensive worldwide public health goals.
Pharmaceutical inventions: The universal phenomenon of parasitic infections traversing afflictions such as malaria, leishmaniasis, and helminth infections is a formidable tool behind the enhanced demand for antiparasitic drugs. The market sales for antiparasitic drugs are soaring, especially pervasive in tropical territories. These contaminations underscore the pressing requirement for a productive cure. In the middle of escalating health implications, there is an escalating essence for progressive antiparasitic drugs. Pharmaceutical inventions in the advancement of antiparasitic drugs become vital, molding an irrepressible market retaliation and enhancing healthcare provocations propounded by these infections.
- Industry Trends:
Advancement in pharmaceutical research: Advancement in pharmaceutical research plays a vital role in the augmentation of antiparasitic drugs market share. Continual progression, traversing inventive prescriptions to futuristic therapeutic game plans, cause elevated productivity and security in antiparasitic drugs. These quantum leap productively solve issues such as drug resistance and untoward impacts thus pushing the market’s advancement. Inventions in delivery arrangements expedited by technological pace enhance cure precision and improve patient conformity.
Contemporary drugs in the antimalarial armaments: Drug development proposed action for malaria accountable for market growth over the forecast period. For instance, in March 2023, a distinct curtailment in malaria prevalence and death has been delineated in recent years because of the initiation of the act in antimalarial policy, the advancement of drug aversion opposed to the majority of antimalarial particularly artemisinin derivatives, is a panicky situation. The initiation of contemporary drugs in the antimalarial armaments is an instant requirement. Depending on resources, one or more of the programs debated should be inspected for the advancement of contemporary chemotherapeutic conflicts for malaria. Pre-eminently, the usage of genomics and omics-dependent procedures has caused a notable leap forward in the recognition of new targets in protozoan illnesses.
- Restraints:
Regulatory provocations exercise influence on the antiparasitic drugs market, influencing several angles of drug development. The stringent consent process ordered by regulatory firms enlarged advancement dockets and raised prices, generating intimidating barricades to market entry. Parasite particular regulatory needs initiate complications in drug advancement and consent procedures, while diligent data demands become notable impediments requiring sizeable resources and time allegiance. Continual post-market supervision needs for drug security and productivity, together with the provocation of observing drug aversion, additionally mess up regulatory deference. Irregularity in guidelines covering dominions translates into global deference provocations, and zestful regulatory topography demands workability in drug advancement schemes. Obtaining accelerated regulatory routes becomes important for punctual consent, but reservation complications create provocations for makers looking for prompt procedures.
Inquire more about this report before purchase @ https://www.polarismarketresearch.com/industry-analysis/antiparasitic-drugs-market/inquire-before-buying
(Inquire a report quote OR available discount offers to the sales team before purchase.)
Segmentation Overview
- Anthelmintics Segment Witnessed a Sharp Rise
Based on type, the anthelmintics segment witnessed a sharp rise. The antiparasitic drugs market demand is on the rise as it is a technical grade of antiparasitic drugs that are carefully deliberated to fight infections created by parasitic worms known as helminths. Functioning by deranging the physiological procedures of parasitic worms, anthelmintics cause the dismissal of these parasites from the host entity. Obtainable in multiple formulations involving oral medications and injectables, anthelmintics are influential in regulating and prohibiting parasitic worm epidemics. Their earmarked movement and productivity render them essential in inscribing the varied provocations indicated by helminthic contamination traversing medical and veterinary petitions.
- The Injectable Segment Dominated the Market
Based on the route of administration, the injectable segment dominated the market. The antiparasitic drugs market trends include that when operated through injections, these drugs convey a speedy and undeviating answer, especially productive in grave cases or when oral management is imperative. Injectable prescriptions guarantee accurate dosing and speedy incorporation, causing prompt and earmarked cures for parasitic illnesses. This method of commanding is frequently engaged in healthcare settings emphasizing its importance in handling and countering parasitic contaminations productively. It is especially advantageous when instant and formidable therapeutic conflict is needed for maximum patient consequence.
Request for a Discount on this Report Before Purchase @ https://www.polarismarketresearch.com/industry-analysis/antiparasitic-drugs-market/request-for-discount-pricing
Antiparasitic Drugs Market: Report Dynamics & Scope
| Report Attribute | Details |
| Revenue Forecast in 2032 | USD 38.20 Billion |
| Market size value in 2024 | USD 25.08 Billion |
| Expected CAGR Growth | 5.4% from 2024 – 2032 |
| Base Year | 2023 |
| Forecast Year | 2024 – 2032 |
| Top Market Players | Bayer AG, Cipla Limited, F. Hoffmann-La Roche Ltd., GlaxoSmithKline, Ipca Laboratories Ltd, among others |
| Segments Covered |
|
| Customization Options | Customized purchase options are available to meet any research needs. Explore customized purchase options |
Regional Insights
North America: This region held the largest antiparasitic drugs market share due to varied geographic topographies displaying diverged pervasiveness of parasitic infections such as malaria and Chagas disease, influencing market demand. Particularly, prominent pharmaceutical companies administer sizeable resources to R&D concentrating on establishing drug formulations. To reinforce their market estimation, these firms engage in deliberate association and assets. Meticulous regulatory caliber supervises drug assent, guaranteeing both security and productivity. North American establishments diligently cause worldwide health ventures inscribing parasitic illnesses. In spite of growth stimulated by enhanced consciousness and detection, provocations such as drug aversion and healthcare imbalances impact market dynamics.
Asia Pacific: This region experienced significant growth as its disease motifs, described by a broad variation of parasitic illnesses such as helminthiasis, leishmaniasis, and malaria, are a prominent element for market growth. The requirement for concentrated pharmacological remedies is underscored by the region's well-defined epidemiological ambiance, which is distinguished by a variation of parasitic disease kinds and pervasiveness.
Browse the Detail Report “Antiparasitic Drugs Market Share, Size, Trends, Industry Analysis Report, By Type (Antiprotozoals, Anthelmintics, Others); By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2024- 2032” with in-depth TOC: https://www.polarismarketresearch.com/industry-analysis/antiparasitic-drugs-market
For Additional Information OR Media Enquiry, Please Mail At: sales@polarismarketresearch.com
Key Questions Addressed in the Report:
- What is the CAGR expected to be recorded for the antiparasitic drugs market?
Ans: The CAGR expected to be recorded for the market is 5.4%
- What is the current and estimated market value of the market?
Ans: The current market value is USD 23.86 billion, and the estimated market value is USD 38.20 billion.
- Which are the major players operating in the industry?
Ans: Some of the major players operating in the industry are AstraZeneca, Bayer AG, and Cipla Limited.
- Which segments are covered by the report?
Ans: The segments covered by the report are type, route of administration, distribution channel, and region.
Polaris Market Research has segmented the Antiparasitic Drugs market report based on type, route of administration, distribution channel, and region:
By Type Outlook
- Antiprotozoals
- Anthelmintics
- Others
By Route Of Administration Outlook
- Topical
- Oral
- Injectable
By Distribution Channel Outlook
- Retail Pharmacy
- Hospital Pharmacy
- Others
By Region Outlook
- North America (U.S., Canada)
- Europe (France, Germany, UK, Italy, Netherlands, Spain, Russia)
- Asia Pacific (Japan, China, India, Malaysia, Indonesia. South Korea)
- Latin America (Brazil, Mexico, Argentina)
- Middle East & Africa (Saudi Arabia, UAE, Israel, South Africa)
Browse More Related Research Reports:
- SiC-On-Insulator and Other Substrates Market Size, Share 2024 Research Report
- U.S. Postal Automation Systems Market Size, Share 2024 Research Report
- North America MRO Distribution Market Size, Share 2024 Research Report
- Pneumatic Conveying Systems Market Size, Share 2024 Research Report
- Health & Hygiene Packaging Market Size, Share 2024 Research Report
About Polaris Market Research:
Polaris Market Research is a global market research and consulting company. The company specializes in providing exceptional market intelligence and in-depth business research services for PMR’s clientele spread across different enterprises. We at Polaris are obliged to serve PMR’s diverse customer base present across the industries of healthcare, technology, semiconductors, and chemicals among various other industries present around the world. We strive to provide PMR’s customers with updated information on innovative technologies, high-growth markets, emerging business environments, and the latest business-centric applications, thereby helping them always to make informed decisions and leverage new opportunities. Adept with a highly competent, experienced, and extremely qualified team of experts comprising SMEs, analysts, and consultants, we at Polaris endeavor to deliver value-added business solutions to PMR’s customers.
Contact:
Likhil G
30 Wall Street
8th Floor,
New York City, NY 10005,
United States
Phone: +1-929 297-9727
Email: sales@polarismarketresearch.com
Web: https://www.polarismarketresearch.com
Blog: https://polarismarketresearch.medium.com
